XBI ETF — SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (XBI)

XBI is an ETF that tracks the S&P Biotechnology Select Industry Index. As of September 4, 2026, its distribution rate is 0.07%, its trailing-12-month yield is 0.35%, its expense ratio is 0.35%. Dividend Vision Distribution Safety Score™ is 72/100 (Generally safe). Total return is 959.5% over the past 20.6 years, 170.1 points ahead of SPY at 789.4%.

SPDR S&P Biotech ETF tracks the S&P Biotechnology Select Industry Index using an equal-weight methodology, holding the securities that comprise this index of biotech companies. The fund has a modest current distribution rate paid quarterly and carries an expense ratio of 0.35%. It appeals to equity investors seeking exposure to the biotechnology sector through a diversified, passively managed approach.

XBI performance versus SPY

Data as of September 4, 2026.

Total return is 959.5% over the past 20.6 years, 170.1 points ahead of SPY at 789.4%. Its deepest 1-year drawdown was 10.5%.

XBI key facts

Data as of September 4, 2026.

Distribution Safety Score™

72 · Generally safe

Safety-Adjusted Yield

0.05%

Issuer

State Street

Asset type

ETF

Asset class

Equity

Inception date

01/31/2006

Expense ratio

0.35%

Distribution rate

0.07%

Distribution frequency

Quarterly

Trailing yield

0.35%

Last close

$163.81

NAV

$165.33

Premium / discount

0.92% discount

AUM

$11,465,141,212

Average volume

3752577.0

Last dividend

$0.138

Last ex-dividend date

06/22/2026

Last payment date

06/24/2026

Beta

1.14

How Dividend Vision calculates yield and returns

Distribution rate (0.07%) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield (0.35%) is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. We show a 30-day SEC yield when the fund publishes one. Schwab and other issuers may report a TTM distribution yield or SEC yield on a different date — all can be valid; they are not interchangeable. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss. Figures below use Dividend Vision data as of September 4, 2026.

Distribution rate methodology · Distribution Safety Score methodology · SEC yield

Sources and review

Data as of September 4, 2026.

Primary sources: State Street or company page; Index: S&P Biotechnology Select Industry Index; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

XBI risks and drawbacks

XBI's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are quarterly, so cash flow is lumpy versus a monthly fund. The deepest 1-year drawdown on record here is 10.5%.

Who may consider XBI — and who may not

It is a weaker fit for investors who need monthly cash flow (XBI pays quarterly); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Compare XBI

XBI vs similar funds:

• XBI vs IBB
• XBI vs ARKG

Frequently asked questions

More securities from State Street.